摘要
目的:趋化因子受体CXCR4在癌转移中起着重要作用。我们研究了乳腺癌标本中CXCR4的不同表达水平以及生物学标记物HER2的表达,进而评估这些生物学标记物能否预测腋窝乳腺癌腋窝淋巴结转移潜能。方法:CXCR4和HER2表达用免疫组化的方法,检测不同时期乳腺癌的石蜡切片。其中淋巴结阳性病例80例,淋巴结阴性病例7例。结果:淋巴结阳性较阴性病例显示CXCR4高表达率(26.3%VS.14.3%,P=0.013),HER2过表达(28.8%vs.14.3%,P=0.011)。CXCR4与HER2表达与乳腺癌肿瘤分期(P=0.000)和淋巴结转移状况(P=0.032)正相关。同时标记CXCR4和HER2,与淋巴结阴性肿瘤比较,淋巴结阳性高表达其中一种标记物(51.3%vs.28.6%,P<0.003)。结论:趋化因子受体CXCR4在乳腺癌中是预测腋窝淋巴结转移的一种新型的生物标记物。联和其他标记物,如HER2可提高预测受累淋巴结的状态。
Objective: To detect the expression of CXCR4 in breast cancer and to investigate its significance in predicting lymph node metastasis. Methods: Paraffin-embedded tissue sections of lymph nodes without metastasis (n=7) and lymph nodes with metastasis (n=80) of breast cancer were detected for the expression of CXCR4 by immunohistoehemistry. Results: The Lymph nodes with metastasis presented with higher rate of cytoplasmie CXCR4 staining (26.3% versus 14.3%, P=0.013) and higher HER2 expression (28.8% versus 14.3%, P=0.011) than that in the lymph nodes without metastasis. The expression of CXCR4 and HER2 was positively correlated with tumor stage and lymph node involvement. Conclusion: The chemokine receptor CXCR4 is a novel biomarker that can predict lymph ,node metastases of breast cancer. Utilization of additional markers, such as HER2, can further help to predict lymph node involvement.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2008年第2期88-91,共4页
Chinese Journal of Clinical Oncology
基金
安徽省自然科学基金(编号:070413119)
安徽省临床医学应用技术研究计划项目(编号:06B105)
蚌埠市科技计划项目资助(编号:200617)
关键词
乳腺癌
免疫组化
肿瘤分期
淋巴结状态
Breast cancer
hnmunohistochemistry
Tumor stage
Lymph node status